



EOCCO POLICY

Policy Type: PA/SP

Pharmacy Coverage Policy: EOCCO186

**Description**

Sodium oxybate (Xyrem) and calcium, magnesium, potassium, sodium oxybates (Xywav) are orally administered metabolites of the neurotransmitter GABA that act as central nervous system depressants with an unknown mechanism of action.

**Length of Authorization**

- Initial: Three months
- Renewal: 12 months

**Quantity Limits**

Product Name	Dosage Form	Indication	Quantity Limit
sodium oxybate (Xyrem)	500 mg/mL	Narcolepsy with cataplexy; Narcolepsy with excessive daytime sleepiness in patients greater than 7 years of age	540 mL/30 days
calcium, magnesium, potassium, sodium oxybates (Xywav)	500mg/mL		540 mL/30 days

**Initial Evaluation**

- I. **Sodium oxybate (Xyrem)** may be considered medically necessary when the following criteria are met:
  - A. Member is seven years of age or older; **AND**
  - B. Medication is prescribed by, or in consultation with, a sleep specialist, psychiatrist, or neurologist; **AND**
  - C. Not used in combination with sedative hypnotic agents (e.g. benzodiazepines, barbiturates, zolpidem tartrate); **AND**
  - D. Confirmation the member does not have a succinic semialdehyde dehydrogenase deficiency; **AND**
  - E. Provider attestation the member does not have a history of substance abuse; **AND**
  - F. A diagnosis of one of the following:
    1. **Narcolepsy with cataplexy; AND**
      - i. Confirmation of cataplexy defined as episodes of sudden loss of muscle tone; **AND**
      - ii. Symptoms have been present for at least three months; **AND**



## EOCCO POLICY

- iii. Documented impairment/limitation of activities of daily living (e.g. missing school/work, household chores, driving); **OR**
- 2. **Narcolepsy with excessive daytime sleepiness; AND**
  - i. Confirmation of diagnosis with a sleep study (including polysomnography and multiple sleep latency test); **AND**
  - ii. Symptoms have been present for at least three months; **AND**
  - iii. For members that are 18 years of age or older, treatment with ALL of the following has been ineffective, contraindicated, or not tolerated:
    - a. Modafinil (Provigil) or armodafinil (Nuvigil); **AND**
    - b. Solriamfetol (Sunosi);
    - c. A stimulant (e.g. methylphenidate, dextroamphetamine); **AND**
  - iv. Documented impairment/limitation of activities of daily living (e.g. missing school/work, household chores, driving)
- II. **Calcium, magnesium, potassium, sodium oxybates (Xywav)** may be considered medically necessary when the following criteria below are met:
  - A. Criteria I(A)-I(F) above have been met; **AND**
  - B. Treatment with sodium oxybate (Xyrem) has been ineffective, contraindicated or not tolerated.
- III. Sodium oxybate (Xyrem) and calcium, magnesium, potassium, sodium oxybates (Xywav) are considered investigational when used for all other conditions, including but not limited to:
  - A. Fibromyalgia
  - B. Idiopathic hypersomnia
  - C. Insomnia

### Renewal Evaluation

- I. Member has received a previous prior authorization approval for this agent through this health plan; **AND**
- II. Member is not continuing therapy based off being established on therapy through samples, manufacturer coupons, or otherwise. Initial policy criteria must be met for the member to qualify for renewal evaluation through this health plan; **AND**
- III. Member has exhibited improvement or stability of disease symptoms (e.g., reduction in cataplexy attacks, improvement in ability to complete activities of daily living, improvement in ability to stay awake); **AND**
- IV. Medication will not be used in combination with sedative hypnotic agents (e.g. benzodiazepines, barbiturates, zolpidem tartrate);



### Supporting Evidence

- I. The American Academy of Sleep Medicine does not make any recommendations on preferring any agents over one another. Other guidance on the treatment of narcolepsy, recommends modafinil and armodafinil as first-line treatment options, stimulants as second-line options due to their adverse event profile, and sodium oxybate (Xyrem) as a third-line option due to its adverse event profile and requirement for a REMS program. Guidelines have not been updated to include calcium, magnesium, potassium, sodium oxybates (Xywav) at this time.
- II. The REMS program only allows certified prescribers and pharmacies to dispense sodium oxybate (Xyrem) and calcium, magnesium, potassium, sodium oxybates (Xywav). Prescribers must screen each patient for a history of alcohol or substance abuse, sleep-related breathing disorders, compromised respiratory function, depression or suicidality, and concomitant use of sedative hypnotics, other CNS depressants, or other potentially interacting agents.
- III. Patients included in clinical trials had a history of narcolepsy for three months or greater and had chronic narcolepsy that was ongoing.
- IV. For the treatment of narcolepsy with cataplexy, sodium oxybate (Xyrem) was evaluated in two randomized, double-blind, placebo-controlled, multicenter, parallel-group trials with a total of 191 patients. Over 80% of patients in these trials were on stimulants as background therapy. The primary efficacy endpoint was the median change from baseline in cataplexy attacks. The baseline number of cataplexy attacks was 20 and 23 for the placebo group and Xyrem 9g group, respectively. Trial one had a reduction of 16 attacks per week in the 9g treatment group and 4 attacks per week in the placebo group ( $p=0.0016$ ). Trial two was a randomized withdrawal trial, and the placebo group had 21 attacks within two weeks, while the sodium oxybate (Xyrem) group had zero attacks within two weeks ( $p<0.001$ ).
- V. For the treatment of narcolepsy with excessive daytime sleepiness, sodium oxybate (Xyrem) was evaluated in two randomized, double-blind, placebo-controlled trials with a total of 450 patients. The primary efficacy endpoint for trial three was the change from baseline in the Epworth Sleepiness Scale (EPSS). Sodium oxybate (Xyrem) had a -2 and -5 median change from baseline at week 8 for the 6g and 9g treatment groups, and both groups had statistically greater reductions than the placebo group ( $p<0.001$ ). The primary efficacy endpoint for trial four was the change from baseline in the Maintenance of Wakefulness Test (MWT). Sodium oxybate (Xyrem) had a mean change from baseline of 0.6 compared to -2.7 for placebo at week 8 ( $p<0.001$ ).
- VI. For the treatment of narcolepsy with cataplexy and excessive daytime sleepiness, sodium oxybate (Xyrem) was evaluated in one double-blind, placebo-controlled, randomized-withdrawal trial with 106 pediatric patients. Patients included in this study were seven to 16 years of age. The primary efficacy endpoints were the change in the frequency of cataplexy attacks and EPSS. The median change from baseline in the number of cataplexy attacks per



## EOCCO POLICY

- week was 0.3 for sodium oxybate (Xyrem) compared to 12.7 for placebo ( $p < 0.0001$ ). The median change in the EPSS was zero for sodium oxybate (Xyrem) and three for placebo ( $p = 0.0004$ ).
- VII. Sodium oxybate (Xyrem) and calcium, magnesium, potassium, sodium oxybates (Xywav) are contraindicated in patients taking sedative hypnotic agents (e.g. benzodiazepines, barbiturates, zolpidem tartrate), and in patients with a succinic semialdehyde dehydrogenase deficiency. Sodium oxybate (Xyrem) and calcium, magnesium, potassium, sodium oxybates (Xywav) have serious side effects such as, central nervous system depression, abuse and misuse, respiratory depression and sleep-disordered breathing, depression and suicidality, parasomnias, other psychiatric reactions (e.g. anxiety, hallucinations, psychosis), and elevates salt content (use with caution in patients that have heart failure, hypertension, or renal impairment).
- VIII. Solriamfetol (Sunosi) is FDA-approved for the treatment of excessive daytime sleepiness associated with OSA and narcolepsy in adults.
- IX. The efficacy and safety of solriamfetol (Sunosi) was established in two Phase 3, multi-center, double-blind, placebo-controlled, randomized trials of fair quality that evaluated the use of solriamfetol (Sunosi) in patients with excessive daytime sleepiness associated with OSA ( $n = 459$ ) or either type I or type II narcolepsy ( $n = 231$ ). Solriamfetol (Sunosi) demonstrated a change in MWT of 7.7 minutes from baseline, and a change in EPSS of -3.8 from baseline, at week 12 ( $p < 0.0001$ ) for both endpoints against placebo.
- X. The efficacy and safety of calcium, magnesium, potassium, sodium oxybates (Xywav) was established in a Phase 3, multi-center, double-blind, placebo-controlled, randomized trial that evaluated the use of calcium, magnesium, potassium, sodium oxybates (Xywav) in patients with narcolepsy with cataplexy. Patients were all transitioned to the use of calcium, magnesium, potassium, sodium oxybates (Xywav) and optimized regardless of prior anti-cataplectic therapy or being naïve to treatment ( $n = 201$ ). Once optimized, efficacy was confirmed in the double blind, randomized withdrawal period (DB RWP) of this trial. During the DB RWP, outcomes showed a statistically significant worsening of cataplexy symptoms in patients on placebo when compared to those in the calcium, magnesium, potassium, sodium oxybates (Xywav) arm. The safety profile in pediatric patients with Xywav is expected to be similar to that of adult patients treated with Xywav and to that of pediatric patients treated with Xyrem.
- XI. The cost of sodium oxybate (Xyrem) and calcium, magnesium, potassium, sodium oxybates (Xywav) is \$18,000 per month at max dose, while solriamfetol (Sunosi) is \$800 per month at max dose.

### Investigational or Not Medically Necessary Uses

- I. Sodium oxybate (Xyrem) and calcium, magnesium, potassium, sodium oxybates (Xywav) have not been FDA-approved, or sufficiently studied for safety and efficacy for the conditions or settings listed below:



# sodium oxybate (Xyrem®); calcium, magnesium, potassium, sodium oxybates (Xywav™) EOCCO POLICY



- A. Fibromyalgia
- B. Idiopathic hypersomnia
- C. Insomnia

## References

1. Xyrem [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc. October 2018.
2. SUNOSI [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc. October 2019.
3. Scammell TE. Treatment of narcolepsy in adults. UpToDate Inc. <https://www.uptodate.com>. (Accessed on April 27, 2020.)
4. Scammell TE. Clinical features and diagnosis of narcolepsy in adults. UpToDate Inc. <https://www.uptodate.com>. Accessed on April 27, 2020.
5. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. *Sleep*. 2007;30(12):1705-11.
6. XyremREMS. Xyrem REMS Program. <https://www.xyremrems.com/>. Accessed April 27, 2020.
7. Xywav [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc. July 2020.

## Policy Implementation/Update:

Action and Summary of Changes	Date
Update to add new to market Xywav with requirement to trial and fail or demonstrate contraindication or intolerance to Xyrem. Updated clinical trial background on Xywav.	10/2020
Transitioned from criteria to policy. Included information on: <ul style="list-style-type: none"> <li>• Requirement to be prescribed by or in consultation with a sleep specialist, psychiatrist, or neurologist</li> <li>• Confirmation of diagnosis for narcolepsy</li> <li>• Requirement for chronic narcolepsy defined as three-month history</li> <li>• Requirement that member has functional impairment for activities of daily living</li> <li>• Updated requirements for trial and failure to one stimulant, and modafinil or armodafinil, and Sunosi</li> </ul>	05/2020
Policy created	02/2012